Expert Guidance on GLP-1 Receptor Agonists in Type 2 Diabetes: A Case-Based Approach

Download All
Learn the glycemic and extraglycemic properties of GLP-1 RA therapies to lower A1C, reduce comorbidity risks, and improve patient adherence and self-care in the management of T2D.
person default
Vanita R. Aroda, MD
person default
Arthi Thirumalai, MBBS

ClinicalThought

How I use GLP-1 receptor agonists to manage patients with type 2 diabetes, and why they warrant broad use across multiple patient populations.

person default Arthi Thirumalai, MBBS Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 18, 2020 Expired: December 17, 2021

An early experience with my mom’s type 2 diabetes taught me the importance of ensuring patients know what to expect when taking a new medication.

person default Vanita R. Aroda, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 29, 2020 Expired: December 28, 2021

On-Demand Webcast

On-demand Webinar focusing on current best practices in leveraging GLP-1 RA therapy in T2D management.

person default Vanita R. Aroda, MD person default Arthi Thirumalai, MBBS Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) Registered Nurses: 1.0 Nursing contact hour Released: December 4, 2020 Expired: December 31, 2021
Provided by the Endocrine Society, in collaboration with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue